D. Blakey

发表

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Mohammad Tabrizi, Steve Emery, Corinne Reimer, 2010, Molecular Cancer Therapeutics.

A versatile system for receptor-mediated gene delivery permits increased entry of DNA into target cells, enhanced delivery to the nucleus and elevated rates of transgene expression

K. Ulbrich, V. Šubr, D. Blakey, 2000, Gene Therapy.

Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.

R. Jain, P. Grodzinski, H. Maeda, 2013, Cancer research.

Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126

Joanna Leadbetter, Lisa Polin, Catherine Wheeler, 2004, Clinical Cancer Research.

MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

S. Barry, J. Kendrew, V. Bedian, 2012, Molecular Cancer Therapeutics.

Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.

F. Howe, J. Griffiths, D. McIntyre, 2005, Neoplasia.

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

J. Nemunaitis, R. Kurzrock, M. Jo, 2015, Science Translational Medicine.

Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126

J. Waterton, P. LoRusso, A. Ryan, 2004, Clinical Cancer Research.

ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.

D. Blakey, M. Stratford, G. Tozer, 2002, Cancer research.

Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.

F. Westwood, A. Ryan, S. Ashton, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Gene activation of CEBPA using saRNA: Preclinical studies of the first in human saRNA drug candidate for liver cancer

J. Rossi, P. Saetrom, N. Habib, 2018, Oncogene.

Adenovirus vector–mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane

S. Emery, D. Blakey, P. Lowenstein, 2002, Cancer Gene Therapy.

Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2‐specific antagonist is associated with reduced tumor growth

S. Barry, S. Ashton, C. Lewis, 2011, International journal of cancer.

Inhibition of Platelet-Derived Growth Factor Receptor α by MEDI-575 Reduces Tumor Growth and Stromal Fibroblast Content in a Model of Non-Small Cell Lung Cancer

P. Hall, Z. Cao, C. Reimer, 2013, Molecular Pharmacology.

Factors Impacting the Tumor Localization and Distribution of Antibody-Based Therapeutics in Oncology

D. Blakey, 2012 .

Anti-Cancer Drug Discovery and Development Summit

D. Blakey, 2003, Expert opinion on investigational drugs.

Sensitization of Tumor-Associated Endothelial Cell Apoptosis by the Novel Vascular-Targeting Agent ZD6126 in Combination with Cisplatin

D. Blakey, S. Sone, S. Yano, 2004, Clinical Cancer Research.

Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.

M. Tabrizi, D. Blakey, S. Coats, 2011, Cancer research.

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

C. Springer, H. Shahbakhti, D. Hochhauser, 2002, British Journal of Cancer.

ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.

C. Springer, D. Blakey, S. Sharma, 1996, Cancer research.

Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).

C. Springer, D. Blakey, I. Niculescu-Duvaz, 1995, Journal of medicinal chemistry.

Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody‐Directed Enzyme Prodrug Therapy (ADEPT).

C. Springer, D. Blakey, I. Niculescu-Duvaz, 1996 .

Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.

D. Blakey, P. Knowles, P. Thorpe, 1987, Cancer research.

Purification of ricin A1, A2, and B chains and characterization of their toxicity.

J. Uhr, D. Blakey, P. Knowles, 1986, The Journal of biological chemistry.

Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo.

R. J. Price, D. Blakey, P. Thorpe, 1988, Biochimica et biophysica acta.

Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model.

F. Howe, J. Griffiths, D. McIntyre, 2004, Neoplasia.

Destruction of cytochrome P-450 and formation of green pigments by contraceptive steroids in rat hepatocyte suspensions.

I. White, D. Blakey, 1986, Biochemical pharmacology.

Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.

C. Springer, D. Blakey, S. Sharma, 1994, British Journal of Cancer.

Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing.

D. Blakey, P. Wentworth, G. Blackburn, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease.

C. Springer, D. Blakey, D. Davies, 1995, Biochemical Society transactions.

Enhancing SIRT1 Gene Expression Using Small Activating RNAs: A Novel Approach for Reversing Metabolic Syndrome.

J. Rossi, D. Blakey, P. Swiderski, 2022, Nucleic acid therapeutics.

The first international conference on vascular targeting: meeting overview.

D. Blakey, D. Chaplin, P. Thorpe, 2003, Cancer research.

The First International Conference on Vascular Targeting : Meeting Overview 1

D. Blakey, D. Chaplin, P. Thorpe, 2003 .

Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting Paracrine Hedgehog Signaling

E. Hurt, R. Hollingsworth, Youzhen Wang, 2013, Molecular Cancer Therapeutics.

Drug targeting with monoclonal antibodies. A review.

D. Blakey, 1992, Acta oncologica.

Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.

N. Habib, D. Blakey, Jon Voutila, 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

Immune Response Modifiers of Biological Origin Chapter 15 IMMUNOTOXINS

D. Blakey, 1992 .

ZD6126: a novel small molecule vascular targeting agent.

F. Westwood, A. Ryan, S. Ashton, 2002, International journal of radiation oncology, biology, physics.

Comparison of the cellular internalization of antibodies used either as immunotoxins or in ADEPT

D. Blakey, A. Wright, P. Pinder, 2007, Cell Biophysics.

Chemotherapy Agents in Preclinical Models Antitumor Activity in Combination with VEGF Inhibitors and A Human Monoclonal Anti-ANG 2 Antibody Leads to Broad

Jeffrey L. Brown, Z. Cao, M. Pinzon-Ortiz, 2009 .

Molecular Cancer Therapeutics A Human Monoclonal Anti-ANG 2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Jeffrey L. Brown, Z. Cao, M. Pinzon-Ortiz, 2009 .

The preparation of deglycosylated ricin by recombination of glycosidase-treated A- and B-chains: effects of deglycosylation on toxicity and in vivo distribution.

D. Blakey, B. Foxwell, P. Thorpe, 1987, Biochimica et biophysica acta.

Antibody toxin conjugates: a perspective.

D. Blakey, P. Thorpe, P. Wallace, 1988, Progress in allergy.

Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue

N. Curtin, D. Newell, D. Blakey, 2001, British Journal of Cancer.

457 Preclinical pharmacology of AZD5312, a generation 2.5 antisense oligonucletotide targeting the androgen receptor with differentiated activity from enzalutamide

M. Jo, B. Davies, D. Blakey, 2014 .

Site-specific conjugation of an enzyme and an antibody fragment.

K. Rose, D. Blakey, R. Offord, 1994, Bioconjugate chemistry.

New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.

D. Blakey, P. Knowles, P. Thorpe, 1987, Cancer research.

Prevention of carbohydrate-mediated clearance of ricin-containing immunotoxins by the liver.

D. Blakey, P. Thorpe, 1988, Cancer treatment and research.

Effect of chemical deglycosylation on the in vivo fate of ricin A-chain.

D. Blakey, P. Thorpe, 1986, Cancer drug delivery.

Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants.

D. Blakey, P. Knowles, P. Thorpe, 1987, Journal of the National Cancer Institute.

Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice

J. Rossi, N. Habib, D. Blakey, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

P. Lyne, B. Monia, D. Blakey, 2017, Science Translational Medicine.

Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.

He-long Zhang, D. Blakey, S. Sone, 2002, Cancer research.

Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

Mohammad Tabrizi, Gadi Gazit Bornstein, Larry L. Green, 2007, Investigational New Drugs.

MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models

J. Rossi, D. Blakey, C. Tan, 2021, International journal of molecular sciences.

Anti-tumor Effects of Monoclonal Antibody-ricin Conjugates In Vitro and In Vivo

D. Blakey, P. Thorpe, 1988 .

Immunotoxins.

D. Blakey, P. Thorpe, 1986, BioEssays : news and reviews in molecular, cellular and developmental biology.

Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer

J. Rossi, P. Saetrom, N. Habib, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma

F. Westwood, A. Ryan, S. Ashton, 2008, British Journal of Cancer.

An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding

S. Barry, S. Wedge, J. Kendrew, 2011, Molecular Cancer Therapeutics.

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo

S. Barry, J. Kendrew, V. Bedian, 2013, Oncogene.

Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells.

R. J. Price, D. Newell, D. Blakey, 1988, Cancer research.

Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.

D. Newell, D. Blakey, P. Knowles, 1988, Cancer research.

DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767.

N. Curtin, D. Newell, D. Blakey, 2002, European journal of cancer.

New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.

T. A. Connors, C. Springer, D. Blakey, 1996, Journal of medicinal chemistry.

Treatment of malignant disease and rheumatoid arthritis using ricin A-chain immunotoxins.

D. Blakey, P. Thorpe, 1988, Scandinavian journal of rheumatology. Supplement.

Unscheduled DNA synthesis caused by norethindrone and related contraceptive steroids in short-term male rat hepatocyte cultures.

I. White, D. Blakey, 1985, Carcinogenesis.

Novel approaches in oncology at AstraZeneca

S. Wedge, D. Blakey, Kate F. Byth, 2003 .

Enzyme prodrug therapy of cancer

D. Blakey, 1997 .

Antitumor effects of an antibody-carboxypeptidase g2 conjugate in combination with a benzoic acid mustard prodrug

C. Springer, D. Blakey, K. Bagshawe, 2009, Cell Biophysics.

Oncologic, Endocrine & Metabolic Enzyme prodrug therapy of cancer

D. Blakey, 1997 .

Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging

J R Griffiths, F A Howe, F. Howe, 2003, British Journal of Cancer.

Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)

N. Curtin, D. Newell, D. Blakey, 2000, British Journal of Cancer.

MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

R. Plummer, T. Meyer, J. Rossi, 2020, Clinical Cancer Research.